Growth Plan for Life Science

Denmark is on an accelerating path towards a transformed future healthcare system which creates new opportunities for innovation – which in itself contributes to further industry growth. The Danish Growth Plan for Life Science sets the ambition to stimulate this potential to the benefit of both public and private stakeholders.

The healthcare industry plays an increasingly important role for Denmark. A strong healthcare industry stimulates research, job opportunities and talent attraction but this cannot be taken for granted. This is why a Life Science Growth Plan was launched in 2018 after consulting the industry. The plan supports further growth of the industry and improves access to new innovative medicines and treatments. The Life Science Growth Plan consists of 36 specific initiatives, targeting barriers and opportunities for the industry across the entire value chain – from research to commercialization, approval and sales in the international export markets.

The Growth Plan's 36 initiatives are clustered around 6 key initiatives.

A key initiative in the Growth Plan is to create a first-class Medicines Agency. The Danish Medicines Agency has made a strategy for 2017-2021, which emphasizes their commitment to both public health and growth in Denmark.

Watch video with Thomas Senderovitz, CEO of The Danish Medicines Agency, about the data driven agency, international collaborations, and data analytics.

Bringing more clinical research to Denmark is another key initiative in the Growth Plan. Trial Nation is a cornerstone in this ambition.